Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs



Rating:

Share or cite this content

Citations should be made in the following way:
S. Avdeev, M. Makarova, Z. Merzhoeva, A. Chuchalin (Moscow, Russian Federation). Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM). Eur Respir J 2014; 44: Suppl. 58, 1519

Member's Comments

No comment yet.

Related content which might interest you: Management of selexipag interruptions in the GRIPHON study Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Lymphangioma in patients with pulmonary lymphangioleiomyomatosis – Results of sirolimus treatment Source: International Congress 2016 – Orphan diseases I Year: 2016 Integrated safety across six clinical trials of alpha-1 augmentation therapy Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Benefit of steroid-free treatment compared to standard therapy (ST) in pulmonary sarcoidosis Source: International Congress 2014 – ILDs 5 Year: 2014 Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015 Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Idiopathic pulmonary fibrosis treatment: Combined pirfenidone + acetylcysteine vs N-acetylcysteine in monotherapy Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Inflammation in COPD patients before and after roflumilast treatment Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab Source: International Congress 2016 – Sarcoidosis Year: 2016 Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effects of inhaled salmeterol/fluticasone on lung function in patients with bronchiectasis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Successful treatment of alveolar proteinosis by inhaled GM-CSF and intravenous rituximab Source: International Congress 2014 – ILDs 5 Year: 2014 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study Source: International Congress 2014 – Sarcoidosis Year: 2014 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 LATE-BREAKING ABSTRACT: Safety and efficacy of inhaled mannitol over 12 months in high-risk patients with non-CF bronchiectasis Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014